R
REGN
Regeneron Pharmaceuticals, Inc. Common Stock
$778.36
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of Regeneron Pharmaceuticals, Inc. Common Stock in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
$40.45
P/E
18.0
Data as of Oct 1
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Expected EPS: $16.36
Oct 30
Posts
No posts about REGN yet.
About Regeneron Pharmaceuticals, Inc. Common Stock
Regeneron Pharmaceuticals develops and sells biotech drugs, most notably Eylea for age-related eye disease and Dupixent, a blockbuster treatment for allergic and inflammatory conditions like eczema and asthma that it co-markets with Sanofi. It also sells the cancer immunotherapy Libtayo and runs a growing pipeline of antibody-based medicines. The company earns money by selling these prescription drugs directly and through royalty and profit-sharing arrangements with partners like Sanofi.